Immunotherapy | Tumor

CURE’s immunotherapy page features the latest cancer news and updates on immunotherapy Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in immunotherapy.

FDA Approves Yervoy for Pediatric Melanoma Population

July 24th 2017, 9:45pm

Article

Yervoy (ipilimumab) was granted approval by the Food and Drug Administration (FDA) for the treatment of pediatric patients who are 12 years old or younger and have unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.

Combination Immunotherapy Being Investigated in Advanced Melanoma

July 10th 2017, 4:58pm

Article

A study pairs an IDO inhibitor with PD-1 checkpoint blockade.

Immunotherapy Combination Is Active in Patients With Melanoma Brain Metastases

June 5th 2017, 7:26pm

Article

Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated a response in some patients with melanoma brain metastases, according to a recent study presented at ASCO.

Using a Virus to Boost Immunotherapy Response in Melanoma

May 31st 2017, 11:12pm

Article

Patients with in immunotherapy-naïve and pretreated patients with advanced melanoma saw a 50 percent overall response rate (ORR) when adding a formulation of the Coxsackievirus A21 (CVA21; CAVATAK®) to Yervoy (ipilimumab) – a combination which was well-tolerated.

How I Remember

May 10th 2017, 8:24am

Article

A plan for remembering your loved one when times get tough.

FDA Approves Bavencio for Bladder Cancer

May 9th 2017, 9:19pm

Article

The Food and Drug Administration has granted an accelerated approval to the PD-L1 inhibitor Bavencio (avelumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Tecentriq Approved as First-Line Treatment for Some Patients With Bladder Cancer

April 18th 2017, 3:13am

Article

The FDA has granted an accelerated approval to Tecentriq as a frontline treatment for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.

With Immunotherapy, Longer Survival May Come With a Cost in Melanoma

April 12th 2017, 11:03pm

Article

Immunotherapy showed improved survival benefits for stage 3 and 4 melanoma, but it came at a price of greater toxicity, according to a randomized, double-blind phase 3 study that compared 10 mg/kg Yervoy (ipilimumab) or a lower dose of the anti-CTLA-4 anticlonal antibody.

Opdivo Is Promising for Advanced Anal Cancer, Study Shows

April 11th 2017, 8:51pm

Article

The PD-1 inhibitor, Opdivo, may be a promising option for patients with advanced anal cancer, according to a recent study.

The Future of Immunotherapy for Urothelial Carcinoma Treatment

April 7th 2017, 9:00pm

Article

In an interview with CURE, Evan Y. Yu, M.D., discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space and the possibilities for the future treatment landscape.